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Abstract 
Gastrointestinal stimulator implants have recently shown positive results in helping obese 
patients lose weight. However, to place the implant, the patient currently needs to undergo an 
invasive surgical procedure. Our team is aiming for a less invasive procedure to stimulate the 
stomach with a gastrostimulator. Attempts covered fully endoscopic implantation and, more 
recently, we have focussed on a single incision laparoscopic procedure. Whatever the chosen 
implantation solution, the electronic design of the implant system shares many challenges. 
This paper covers the work achieved to meet these. 
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 Obesity has reached epidemic proportions with 2.1 
billion overweight adults (Body Mass Index above 25) 
and 600 million obese adults (BMI above 30) 
worldwide.
1-3
 Obesity is commonly associated with 
major health problems and each year, obesity is 
responsible for millions of deaths.
2-4
 Bariatric surgery 
can be efficient in dealing with this issue but they are 
invasive operations performed either by multi-incision 
laparoscopy or even open surgery. Besides, they 
represent a large portion of annual health-care 
expenditures and are limited to patients whose BMI is 
superior to 35.
5
 Gastrostimulation has been demonstrated 
to induce weight loss in humans.
6-8
 However, current 
gastrostimulators are bulky and are implanted by multi-
incision laparoscopy, a relatively expensive and invasive 
procedure. This project aims to implant the device 
through a less invasive procedure. Our designs have 
covered fully endoscopic procedure and, more recently, a 
single incision laparoscopic procedure. Whatever the 
chosen implantation solution, the electronic design of 
these gastrostimulators shares many challenges. From an 
engineering point of view, compared to currently 
available stimulators, we are aiming to: 
 reduce the dimensions and weight of the device while 
protecting it from its environment, 
 provide a stable anchoring, 
 provide a reliable implantation method to place and 
attach the device. 
This paper presents the design and implementation of 
these novel gastrostimulators with validation on a test 
bench and ex-vivo 
Materials and Methods 
A. Electronic design 
The stimulation protocol is based on that of the Enterra 
by Medtronic, which has already achieved good results 
with electrodes near the pylorus in humans,
7,8
 and at 
the pylorus in dogs.
9
 The protocol consists of sending 
trains of current pulses for two seconds every five 
seconds. Each train is composed of 5 mA pulses, 
lasting 330 μs, repeated every 25 ms. Fig. 1 shows a 
block diagram of the implant, including a rechargeable 
battery, a voltage boost (to raise the battery voltage), a 
microcontroller (for the timing and circuit 
synchronisation) and the stimulation circuit. Briefly, 
the current source is based on an operational amplifier 
driving the gate of a transistor. A microcontroller is 
used to drive the amplifier at the desired frequency. 
We expect in situ impedance ranging from 200 to 800 
Ω 10-14 A 2.2 F blocking capacitor will ensure a null 
mean charge. A depletion transistor is used to limit the 
discharge current to at most 20% of the stimulation 
current. During the stimulation phase, the depletion 
transistor is blocked and the current goes through the 
electrodes. During the discharge period, the capacitor 
discharges through the stomach impedance and the 
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depletion transistor. Finally, a boost circuit powered by a 
3.5 V battery supplies the power to the circuit. The 
layout was drawn on a 16 mm diameter substrate. The 
stimulation occurs at the pyloric sphincter, which was 
chosen to anchor the device. Two cylinders linked by a 
flexible body form the implant and are designed to be 
endoscopically placed on each side of the pylorus. One 
cylinder hosts the electronics and delivers the 
stimulation through surface electrodes (see Fig. 2). The 
other contains the power supply. 
B. Choice of materials 
To minimise the device’s overall weight and volume, we 
have opted to protect the electronics by encapsulation 
with silicone rubber. In the case that the implant is 
placed in the stomach, it should also resist its acidic 
environment. This method is well-established for human 
implants,
15
 but has never been used for devices operating 
in the stomach, where the very low pH presents a new 
challenge. The success of this protection relies on the 
long-term stability of the bond between the encapsulant 
and the substrate on which the circuit is built.
16
 
Therefore, several couples of substrate and adhesive 
were tested following PEK Donaldson’s method.17  
The long-term stability of the adhesive bond between 
several couples of substrate and adhesive immersed in 
simulated gastric liquid was the topic of a previous 
publication.
18
 Two silicone rubbers were tested on 
typical implant substrates at worst-case stomach pH. 
Lap-shear tests showed the MED4-4220/alumina couple 
offered the best adhesion with a mean time to failure 
(MTF) of 30 days at 100°C, resulting in a large predicted 
MTF at body temperature (7 years). The MED4-
4220/FR4 couple also had a high MTF of 25.1 days (6 
years). FR4 substrate was chosen to manufacture 
prototypes of the implant as FR4 substrates can be 
ordered directly from usual commercial suppliers. 
C. Manufacturing of the implant 
Cleanliness during the encapsulation process strongly 
influences the implant's lifetime.
16
 Briefly, the cleaner 
the circuit and the substrate, the higher the osmotic 
gradient, should water vapour, which will rapidly 
permeate the encapsulation layer, find a condensation 
site. Liquid water formations would therefore be 
limited, and what would form would be highly 
resistive, hence limiting further loss of adhesion, and 
corrosion. Therefore, the devices were thoroughly 
cleaned using isopropanol and alkaline cleaning 
solution, and rinsed in flowing de-ionised water. A 
dedicated mould has been built to encapsulate the 
implant. The design of the mould allows a protection 
layer of silicone rubber of 2 mm above the components 
and of 0.5 mm above the substrate on the side without 
components. The encapsulation was realised using a 
vacuum centrifuge. The design of the mould allows the 
3 x 3 mm surface electrodes to remain uncovered by 
silicone rubber. The encapsulate implant, which is 17 
mm diameter and 5.5 mm thick, allows endoscopic 
passage through the mouth. 
The battery was dip-coated with Dow Corning 3140 
silicone rubber and the procedure was repeated until 
the layer of the silicone rubber was sufficiently thick. 
Each new affixed layer of silicone rubber was degassed 
and dried before the next dip. DC3140 was selected for 
dip-coating as it forms a thin layer and dries in a few 
minutes in a humid environment at room temperature. 
This silicone rubber is, however, not authorised for 
human implantation. It was used only for this 
prototyping stage and no adhesion tests were 
performed between DC3140 and the material of the 
battery case.  
Low temperature sterilisation using gas plasma 
technology (Sterrad sterilisation) was used for the 
implant and the battery, avoiding a potential melding 
of the silicone rubber and degradation of the battery. 
Steam sterilisation (autoclave) was used for all the 
material not based on silicone rubber, and that could 
withstand the elevated temperature 
Results 
A. Stimulation protocol and load range 
To validate the stimulation protocol, an implant was 
used in continuous mode (trains repeated without 
interruption) with a load between 200 and 800 Ω. The 
implant delivers 5 mA pulses, 330 µs wide with a 
period of 25 ms. The trains last 2 s and are repeated 
 
 
Fig 1.  Block diagram of the implant 
 
 
Fig 2.  Anchoring method of implant at pylorus 
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every 5 second, giving 12 bursts per minute. Fig. 3 
shows two successive trains of pulses (blue curve) and 
the power supply voltage (green curve). The behaviour 
of the implant was validated with a load modelled by a 
resistor connected between the electrodes. We started 
with a 200 Ω load, increased in steps of 200 Ω. The 
implant worked properly from 200 to 1200 Ω, i.e. in a 
larger range that the one required (between 200 and 800 
Ω): correct pulses were delivered and a complete 
discharge of the current was achieved within the 25 ms. 
From 1400 Ω, the  stimulation waveform is affected, 
with longer pulses duration and lower stimulating 
current. 
B. Power requirement 
The power consumed by the implant is due to the 
microcontroller (71 %), the output stage (27 %) and the 
amplifier (2%). Note that the output stage includes a 
boost DC/DC converter to increase the battery voltage 
(around 3.3V) to the 8V required for the stimulation. The 
chosen boost (LT3464) uses a discontinuous mode.  
1. Output stage consumption (stimulation phase)  
Fig. 4 shows that during a stimulation pulse, the 
instantaneous current from the battery reaches peaks of 
75 mA. The boost is therefore working in a 
discontinuous mode, as expected. Therefore, during 
pulse delivery, an average current of 16 mA is drawn 
from the battery (see red curve on Fig. 4). 
With its output voltage of 3.5 V (directly measured at 
the battery output) the battery outputs a power of 56 
mW. The output voltage and output current of the 
boost are respectively 8 V and 5 mA, hence the power 
delivered is 40 mW, leading to an efficiency of 71% 
for the boost during stimulation. 
The discontinuous mode of the boost induces important 
current peaks demand to the battery cell. Unfortunately 
commercially available implantable battery cells are 
not able to deliver such important peaks. The resulting 
output voltage drop can go below the minimum 
operating voltage of 2.1 V and cause stimulation to 
abort, as shown in Fig. 5. An additional capacitor is 
placed in parallel with the battery to smooth the current 
spikes. 
2. Output stage consumption (quiet phase) 
Fig. 6 shows that the instantaneous current 
consumption of the boost also reaches peaks up to 75 
mA, repeated at 20 Hz. 
 
 
Fig 3.  Monitoring of the pulses train 
 
Fig 4.  Current peaks and average current consumed 
during stimulation: the green curve is the input 
voltage of the amplifier, the blue curve represents 
the instantaneous current consumption and red 
curve is the average current consumption 
computed over the current peaks. 
 
 
Fig 6.  Output voltage of the boost (blue curve) and 
current consumption (green curve) during 
quite phase 
 
Fig 5.  2nd stimulation aborted due to voltage drops 
at the battery cell without added capacitor 
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3. Implant consumption and lifetime 
The implant total average current equals 370 µA. It is 
mainly due to the microcontroller (264 µA) and the 
output stage (84 µA during stimulation and 17 µA during 
rest). Note that quiescent currents of the components 
were too small to measure and were therefore derived 
from their datasheets. 
Commercially available batteries from EaglePicher, 
Greatbach, Quallion and Saft were considered. And we 
found energetic densities no higher than 1595 
mWh/cm3. Using this kind of battery, the implant 
lifetime would reach 51 days per cubic centimetre 
C. Minimum required voltage. 
Since the implant is powered by a battery cell, the input 
power voltage is constantly decreasing. Fig. 7 shows the 
behaviour of the implant when the battery voltage 
decreases. When the battery voltage falls below 2.1 V no 
pulse is delivered anymore. At 2.1 V, the microcontroller 
is not capable of delivering the desired output values. At 
2 V, the boost is not capable of working properly. The 
implant stopped working without inducing any damages 
D. Ex-vivo validation 
The stimulator was tested ex-vivo on an animal model to 
prove the functionality of the stimulator and verify the 
correct propagation of stimuli. The stimulator was 
surgically implanted in a dog cadaver. Needle recording 
electrodes (Biopac - Stim Ndl Electrode, BNC – 
ELSTM2) were implanted near the stimulation site and 
connected to an oscilloscope (Tektronix TDS 1002). 
Printed FR4 substrates were ordered from Eurocircuits 
and recessed surface electrodes were used. The 
stimulator was successfully attached to the stomach. 
Stimulation pulses were observed using the oscilloscope 
(Fig. 8). This confirms the functionality of the electronic 
design and a good contact between the implant's 
electrodes and the tissue.  
Recordings were realised with the needle electrodes 
positioned near the stimulation site. The exact position 
of the electrodes was not measured as this test did not 
aim to study the amplitude of the pulses. Correct trains 
of pulses, i.e. at the correct frequency, were observed 
near the stimulation site (see Fig. 8). This is indicative 
of a good contact between the implant electrodes and 
the stomach tissue, good propagation of the pulses and 
that the implant works properly in an ex-vivo 
environment 
Discussion 
We presented design and implementation of a 
gastrostimulator, allowing to reduce the dimensions 
and weight of the devices while still protecting them 
from the low pH stomach environment mimicked in a 
bench test. The method was validated on a test bench 
and ex-vivo. In-vivo validation of the stimulator has 
also been achieved on several dogs and will be detailed 
in a future extended article. 
Future steps will assess the effect of the gastric 
stimulation in vivo. Active stimulators will be 
surgically implanted in dogs to assess the weight loss 
during stimulation. Different stimulation protocols will 
be tested during the experiment. The impact on the 
gastric slow waves, specific hormones and the amount 
of food ingested will be monitored to assess the 
physiological impact of the selected stimulation 
protocol. 
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Fig 8.  Measured pulses during the stimulation of 
the dog's cadaver stomach 
 
 
Fig 7.  Effect of the decrease of the battery cell 
voltage (purple) on the stimulation (blue) and the 
boost voltage (red). 
 
Design and implementation of a less invasive gastrostimulator 
Eur J Transl Myol 26 (2): 129-133 
- 133 - 
 
Conflict of Interest 
The author declare no potential conflict of interests. 
Corresponding Author 
Laurent Lonys, Université Libre de Bruxelles, 1050 
Brussels, Belgium (phone: 32-650-60-66; fax: 32-650-
47-13), E-mail: llonys@ulb.ac.be  
E-mails of coAuthors 
Anne Vanhoestenberghe: a.vanhoest@ucl.ac.uk; Vincent 
Huberty: Vincent.Huberty@erasme.ulb.ac.be; Martin 
Hiernaux: Martin.Hiernaux@endotools.be; Nicolas 
Cauche: Nicolas.Cauche@ulb.ac.be; Nicolas Julémont: 
njulemon@ulb.ac.be; Adrien Debelle: 
addebell@ulb.ac.be; François Huberland: 
Francois.Huberland@ulb.ac.be; Vicente Acuña: 
Vicente.Acuna.Otarola@ulb.ac.be; Carmen Godfraind: 
Carmen.Godfraind@ulb.ac.be; Jacques Devière: 
Jacques.Deviere@erasme.ulb.ac.be; Alain Delchambre: 
Alain.Delchambre@ulb.ac.be; Pierre Mathys: 
pmathys@ulb.ac.be; Antoine Nonclercq: 
anoncler@ulb.ac.be 
References 
1. Finucane MM, Stevens GA, Cowan MJ, et al. 
National, regional, and global trends in body-mass 
index since 1980: systematic analysis of health 
examination surveys and epidemiological studies 
with 960 country-years and 9.1 million participants. 
Lancet. 2011;377(9765):557-67. doi: 10.1016/ 
S0140-6736(10)62037-5. 
2. Dobbs, R., Sawers, C., Thompson, et al. 
Overcoming obesity: An initial economic analysis. 
McKinsey Global Institute 2014. 
3. Ng M, Fleming T, Robinson M,et al. Global, 
regional, and national prevalence of overweight and 
obesity in children and adults during 1980 – 2013 : 
a systematic analysis for the Global Burden of 
Disease Study. Lancet. 2014 Aug 
30;384(9945):766-81. doi: 10.1016/S0140-6736 
(14)60460-8.  
4. Drieskens S, Van der Heyden J, Demarest S, 
Tafforeau J. Is the different time trend (1997-2008) 
of the obesity prevalence among adults in the three 
Belgian regions associated with lifestyle changes? 
Archives of Public Health/Archives Belges de 
Santé Publique, 2014;72:18. doi.org/10.1186/2049-
3258-72-18. 
5. Weiner JP, Goodwin SM, Chang H-Y,et al. Impact 
of Bariatric Surgery on Health Care Costs of Obese 
Persons: A 6-Year Follow-up of Surgical and 
Comparison Cohorts Using Health Plan Data. 
JAMA Surg 2013;148:555-62. doi: 10.1001 
/jamasurg.2013.1504. 
6. Hasler WL. Methods of gastric electrical 
stimulation and pacing: a review of their benefits 
and mechanisms of action in gastroparesis and 
obesity. Neurogastroenterol Motil 2009;21:229-
43. doi: 10.1111/j.1365-2982.2009.01277.x. 
7. Cigaina V. Long-term follow-up of gastric 
stimulation for obesity: the Mestre 8-year 
experience. Obes Surg 2004;14 Suppl 1:S14-22. 
8. Shikora SA. “What are the yanks doing?” the US 
experience with implantable gastric stimulation 
(IGS) for the treatment of obesity—update on the 
ongoing clinical trials. Obes Surg. 2004 Sep;14 
Suppl 1:S40-8. 
9. Xu X, Zhu H, Chen JDZ. Pyloric electrical 
stimulation reduces food intake by inhibiting 
gastric motility in dogs. Gastroenterology. 2005 
Jan;128(1):43-50. 
10. Ayinala S, Batista O, Goyal A, et al. Temporary 
gastric electrical stimulation with orally or PEG-
placed electrodes in patients with drug refractory 
gastroparesis. Gastrointest Endosc. 2005 
Mar;61(3):455-61. http://doi.org/10.1016/S0016-
5107(05)00076-3  
11. Deb S, Tang S-J, Abell TL, et al. An endoscopic 
wireless gastrostimulator (with video). Gastro-
intestinal Endoscopy, 2012;75:411–5, 415.e1. 
http://doi.org/10.1016/j.gie.2011.09.052 
12. Elfvin A, Andersson S, Abrahamsson, et al. Per-
cutaneous implantation of gastric electrodes - A 
novel technique applied in animals and patients. 
Neurogastroenterol Motil 2007;19:103-9. 
http://doi.org/10.1111/j.1365-2982.2006.00858 .x 
13. Familoni BO, Abell TL, Nemoto D, Voeller G, 
Johnson, B. Electrical Stimulation at a Frequency 
Higher than Basal Rate in Human Stomach. Dig 
Dis Sci 1997;42:885-91.http://doi.org/ 10.1023/ 
A:1018804128695 
14. McCallum RW, Lin Z, Forster J, Roeser K, Hou 
Q, Sarosiek I. Gastric Electrical Stimulation 
Improves Outcomes of Patients With 
Gastroparesis for up to 10 Years. Clin 
Gastroenterol Hepatol 2011;9:314-9.e1. doi: 
10.1016/j.cgh.2010.12.013.  
15. Brindley GS. The first 500 sacral anterior root 
stimulators: implant failures and their repair. 
Paraplegia 1995;33:5-9. doi:10.1038/sc.1995.3 
16. Vanhoestenberghe A, Donaldson N. Corrosion of 
silicon integrated circuits and lifetime predictions 
in implantable electronic devices. J Neural Eng 
2013 Jun;10(3):031002. doi: 10.1088/1741-2560/ 
10/3/031002.  
17. Donaldson PEK. Aspects of silicone rubber as 
encapsulant for neurological prostheses. Part 4: 
Two-part rubbers. Med Biol Eng Comput 
1997;35:283-6. 
18. Lonys L, Vanhoestenberghe A, Julémont N, et al. 
Silicone rubber encapsulation for an 
endoscopically implantable gastrostimulator. Med 
Biol Eng Comput 2015;53:319–29. http://doi.org/ 
10.1007/s 11517-014-1236-9. 
 
